538 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This case report is crucial as it highlights a potential, albeit rare, adverse event associated with Tirzepatide that could have significant implications for patient safety and clinical practice. Given the widespread …
This study provides robust real-world evidence supporting the favorable cardiovascular safety profile of tirzepatide, particularly concerning heart failure and arrhythmias, in a diverse patient population. The consist…
This study provides crucial evidence that early intervention with tirzepatide and semaglutide can significantly mitigate the progression of atherosclerosis, a leading cause of morbidity and mortality worldwide. The ob…
This case report provides compelling preliminary evidence suggesting a novel therapeutic avenue for Tirzepatide beyond its established metabolic indications. The observed improvements in autonomic dysfunction and POTS…
This case highlights a rare but potentially life-threatening adverse event associated with Tirzepatide use, particularly in individuals without pre-existing diabetes. It underscores the critical importance of educatin…
This real-world evidence strongly reinforces the efficacy and safety of Tirzepatide for managing Type 2 Diabetes and associated metabolic abnormalities in a broader, more diverse patient population than typically seen…
The initiation of this Phase IV trial is a significant step, as it explores a novel therapeutic avenue for Idiopathic Intracranial Hypertension (IIH), a condition with limited effective treatments. Tirzepatide, known …
The finding that tirzepatide pharmacokinetics are not significantly altered by renal impairment is highly significant. This suggests that patients with kidney disease, including those with end-stage renal disease (ESR…
This research holds significant promise for a population in dire need of improved treatment options, as patients with schizophrenia and AUD face unique challenges and poorer prognoses. If successful, this study could …
This study is critical because it directly addresses a common clinical scenario: how to optimize treatment for Type 2 Diabetes patients who may not be achieving their goals on existing GLP-1 RA therapy. The expected s…
This trial represents a paradigm shift in Type 1 Diabetes management, potentially transforming daily life for millions by simplifying insulin delivery and reducing mental burden. If successful, tirzepatide could enabl…
Obesity-related male infertility is a growing concern, and current treatments often lack sustained efficacy or adherence. This trial holds the potential to identify a novel and effective pharmacological intervention f…
This case report holds significant clinical importance as it expands the known adverse event profile of Tirzepatide, alerting clinicians to the possibility of drug-induced liver injury. While such events are rare, rec…
This real-world comparative study provides crucial insights into the relative effectiveness of leading weight loss medications outside of controlled clinical trials. The findings strongly support Tirzepatide's superio…
This study provides critical early insights into the potential cardiovascular protective effects of Tirzepatide, even before the official results of SURPASS-CVOT are released. The predicted 23% MACE reduction is highl…
While specific numerical outcomes from this completed trial (NCT03882970) are not detailed in the provided record, the study's primary objective was to demonstrate the superior efficacy of tirzepatide in improving gly…
This research holds significant promise as tirzepatide could represent an innovative approach to effectively induce weight loss and inhibit tumor growth in obesity-driven endometrial cancer. Given the strong link betw…
The successful integration of Tirzepatide into OUD treatment could represent a paradigm shift in how we manage this complex disorder, offering a much-needed adjunctive therapy beyond current standards. Given Tirzepati…
As an active study (NCT07417618) not yet recruiting, specific results are not available; however, based on existing clinical trial data and the known mechanisms of these drugs, the study is expected to reveal signific…
This comprehensive network meta-analysis provides robust evidence confirming the superior efficacy of GLP-1 receptor agonists in achieving clinically significant weight loss in nondiabetic adults. The findings highlig…
This case report is significant as it contributes to the emerging understanding of tirzepatide's potential adverse effects, specifically hepatotoxicity. The finding highlights the importance for clinicians to consider…
If BGM0504 demonstrates comparable or superior efficacy and safety to Tirzepatide, it could represent a significant advancement in the treatment landscape for obesity. A new therapeutic option would provide clinicians…
The termination of this Phase 2 study means a potential avenue for enhanced obesity treatment in older adults remains unexplored. While tirzepatide is highly effective, combination therapies are often sought to improv…
This Randomized Control Trial is highly significant as it explores a novel strategy to enhance the effectiveness of bariatric surgery, potentially offering a more robust solution for severe obesity. If successful, com…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
This study is significant because it addresses the complex interplay between inflammatory bowel disease and metabolic health, a common but often unaddressed clinical challenge. The key implication is that a combined t…
This case report is significant because it raises awareness of a potentially novel adverse event associated with tirzepatide, a widely used and highly effective medication. If a causal link were established, it would …
This comprehensive meta-analysis provides compelling and robust evidence that GLP-1 and dual GIP/GLP-1 receptor agonists offer substantial and multifaceted benefits for obese patients with HFpEF, extending significant…
This research highlights the superior patient experience and satisfaction associated with switching to Tirzepatide over escalating Dulaglutide in Type 2 Diabetes management. These findings provide crucial real-world e…
This critical appraisal underscores a crucial safety consideration for tirzepatide, a widely used and highly effective medication for type 2 diabetes and obesity. The identified increased risk of biliary diseases nece…
These findings provide compelling real-world evidence supporting tirzepatide's superior efficacy over sitagliptin not only in glycemic control and weight management but critically, in reducing cardiovascular events in…
The potential success of this combination therapy could represent a significant advancement in the treatment landscape for obesity and overweight. By potentially enhancing the already impressive effects of tirzepatide…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
This Phase II IMPACT-ADT trial is profoundly important as it directly addresses a major unmet need in prostate cancer survivorship, aiming to mitigate the severe cardiometabolic side effects of Androgen Deprivation Th…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to effectively treat Binge-Eating Disorder alongside its established benefits for obesity represents a significant advancement in metabolic and psy…
These findings are highly significant, establishing Tirzepatide as a potentially superior treatment option for individuals with Type 2 Diabetes who are at high risk for cardiovascular events. The dual benefits of subs…